Antiviral Drugs Market Overview & Trends:
The antiviral drugs market size was valued at USD 57.32 billion in 2024 and is expected to reach USD 86.59 billion by 2032, growing at a CAGR of 5.34% over the forecast period of 2025-2032.
The global antiviral drugs market is projected to witness a steady CAGR in the forecast period on account of an increase in the prevalence of viral infections such as HIV, hepatitis, influenza, etc., and new cases of viruses such as COVID-19. Investors are also boosting demand for Gilead as long-acting therapies, increasing access to generics, and global health initiatives take form. Market expansion is driven by high adoption rates in developed regions and the expansion of treatment access in low- and middle-income countries. R&D on antiviral drug development is also in progress, and regulatory assistance has been fueling the antiviral drugs market growth.
The U.S. antiviral drugs market size was valued at USD 18.45 billion in 2024 and is expected to reach USD 27.07 billion by 2032, growing at a CAGR of 4.95% over the forecast period of 2025-2032.
The North American antiviral drug market growth is led by the U.S. owing to the large presence of healthcare facilities, high penetration of drugs for the treatment of HIV and Hepatitis, and the presence of players from leading global companies. Its leadership in the region is more assured with ongoing R&D investments and widespread availability of both originator and generic antivirals.
- Lenacapavir’s bi-annual injectable (Yeztugo) was cleared and endorsed by the FDA and WHO in June–July 2025 for treatment and PrEP, representing a game-changing development for long-acting HIV prevention
Global Antiviral Drugs Market Dynamics:
Drivers
- Increasing Incidence of Chronic Viral Infections to Propel the Market
The global prevalence of chronic viral infections, especially human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), hepatitis B, and hepatitis C, has generated a steady market for antiviral drugs. Such infections typically need chronic or lifelong treatment and are thereby significant contributors to the continued use of antivirals. For example, people living with HIV depend on daily antiretroviral therapy (ART) to sustain viral suppression. Hepatitis B and C patients also need antiviral therapy to avoid liver damage, cirrhosis, and cancer. As diagnostic availability and screening programmes increase globally, more cases are being detected, driving increased treatment acceptance and market growth.
- In 2024, there were an estimated 1.3 million new HIV infections globally, and the ongoing availability of ART and related supportive care is evident.
- Hepatitis C infection remains an affront to global health, with an estimated 50 million individuals infected globally. The development of direct-acting antivirals (DAAs), recognized as a treatment revolutionized the treatment of hepatitis C with highly effective and well-tolerated oral regimens that can cure the infection (Harvoni, Epclusa, Mavyret).
- Advances in Antiviral Drug Development are Accelerating the Market Growth
In recent years, there have been many advances in the area of antiviral drug discovery focused on identifying compounds with new modes of action, greater potency, and improved patient compliance. Drugs such as lenacapavir (an HIV capsid inhibitor) and molnupiravir (for COVID-19) are a new class of targeted antivirals. Long-acting injectables and single-dose oral therapies that have been developed have lightened the load of daily dosing and improved compliance. These advances not only increase the possibility of treatment, but also beckon ready approval through regulatory fast-track application and funding assistance that expedite market growth.
- ViiV Healthcare extended agreements in July 2025 to allow the generic supply of its long-acting cabotegravir/rilpivirine combination in 133 scarce-priority nations, to make it more affordable and accessible.
- Cdara Therapeutics unveiled robust Phase 2 data for its potential long-acting antiviral for flu, CD388, which demonstrated 58–76% protection over 24 weeks, making it a universal flu treatment.
Restraint
- The High Cost of Antiviral Therapies is Hampering the Growth of the Market
Exorbitantly priced antiviral drugs are a major obstacle for broad access, particularly in low- and middle-income countries. Many of the newer, more effective antivirals, from direct-acting antivirals (DAAs) for hepatitis C to long-acting injectables for HIV, are patented and priced at a premium. This leads to affordability issues for individual patients and public health systems. Pricing discrepancies persist even as Indian firms started selling specialized generic versions since April due to limited local production, intellectual property rights, and distribution challenges. This leaves millions of patients either under-treated or, in some cases, unable to access life-saving medicines, undermining the overall effectiveness of disease control initiatives and the pace at which markets grow.
Antiviral Drugs Market Segmentation Analysis:
By Type
The branded segment dominated the antiviral drugs market share in 2024 with a 65.23%, attributed to the high consumption of branded treatment for chronic viral infections, such as HIV, hepatitis B and C, and COVID-19. Most first-line therapies are either injectable or are combinations of antivirals that are not protected by the patent and are produced mostly by the multinational leading companies such as Gilead Sciences, Merck, or GSK. These patented products are typically backed by substantial clinical studies, marketing initiatives, and reimbursement schemes in the developed regions, and this has found expression in the continued dominance of these agents in higher-income markets.
The generics segment is expected to witness the fastest growth throughout the forecast period due to higher consumption in terms of cost in the emerging markets. With blockbuster antivirals coming off patent, generic suppliers are quickly filling the need with affordable options, especially in countries with high prevalence of disease and constrained health care budgets. Generic antiviral drugs will emerge as a massive opportunity, driven by government initiatives, international donor support, and increasing local manufacturing capacity in regions such as APAC, Latin America & Africa.
By Drug Class
The reverse transcriptase inhibitors segment, which has applications in HIV and Hepatitis B treatment, had a market share of 36.4% in 2024. The inhibitors (which include tenofovir, lamivudine, and emtricitabine) are a key component of highly active antiretroviral therapy (HAART), the reference standard in the treatment of HIV infection around the globe. Their widespread application in proprietary and generic products and the strong presence in the North American, European, and Asian markets have made this class the foundation of antiviral therapy. Furthermore, government-sponsored HIV treatment plans and high acceptance in global health recommendations have further buttressed their market leadership.
DNA polymerase inhibitors segment is expected to witness fastest growth over the forecast period due to rising prevalence of diseases such as herpes simplex virus (HSV), cytomegalovirus (CMV), and hepatitis B as these antivirals act upon the replication of viral DNA, due to which these are effective for chronic and latent infections which are managed over long period. Growing immunocompromised populations, such as organ transplant recipients and cancer patients, are also driving the demand for CMV and HSV treatment.
By Application
The HIV/AIDS segment dominated the global antiviral drugs market in 2024 with a 44.1% market share, attributed to the high burden and treatment is lifelong. ART and antiretroviral drugs, the number of people living with HIV globally, 40 million according to WHO. Stagnating prices and increasing average treatment costs revolve around a strong and consistent demand for ART. The adoption is also getting a boost from new treatment regimens, including long-acting injectables and single-pill combinations. In addition, government-sponsored programs, global health initiatives such as PEPFAR and the Global Fund, and large public-private partnerships have set the stage for widespread availability of HIV medicines, especially in high-burden areas.
By Route of Administration
The oral segment dominated the antiviral drugs market in 2024 with a 62.18% market share, owing to high patient compliance, easy administration, and wide market reach. Antivirals taken by mouth are used to treat major viral infections such as HIV, hepatitis B, and hepatitis C, while antivirals you apply to the skin around the mouth are used to treat viral infections such as oral herpes. Many first-line drugs — such as tenofovir, lamivudine, and acyclovir — come in oral formulations that can be brand-name or generic. Oral antivirals also have little administration complexity, cost less, and are available in many countries via retail and hospital pharmacies, which collectively is an advantage of oral antivirals in international markets.
Parenteral segment is projected to be the fastest-growing application during the forecast period, owing to increasing acceptance of long-acting injectable treatments for chronic diseases such as HIV. Novelties such as cabotegravir/rilpivirine and lenacapavir have been presented, allowing longer intervals between doses, increasing adherence, and limiting the burden of daily medication. Also, parenteral antivirals are widely used in UHs for acute viral infections such as severe influenza or COVID-19 in high-risk patients. With the approvals and use of more advanced injectables, especially in developed pockets, the parenteral space is set to witness faster growth.
By Distribution Channel
The hospital pharmacy segment dominated the antiviral drugs market in 2024 with a 58.2% market share, owing to the high prevalence of acute and chronic viral infections and the corresponding large patient pool requiring treatment in hospitals. Antiviral therapies, especially those needing intravenous treatment or closer monitoring by a medical professional (e.g., severe COVID-19, complications of HIV/AIDS, viral infections following transplant), are commonly started and managed in a hospital. Hospitals are also vital to the stockpiling and administration of new or expensive antiviral treatments.
The online pharmacy segment is projected to register the highest CAGR during the forecast period, owing to the digitalization of healthcare and growing consumer inclination toward availing prescription refilling services at home. During the COVID-19 pandemic, there was an increase in the use of online platforms for chronic medication refill, such as HIV antivirals and treatment for hepatitis. Advancements in e-prescription, support from the regulatory framework for digital pharmacy models, and expanding reach of licensed e-commerce pharmacy services are facilitating wider penetration, predominantly in the urban markets.
Regional Insights:
North America dominated the antiviral drugs market with a 42.3% market share in 2024 due to its well-developed health care infrastructure, increased awareness of viral diseases, and availability of advanced treatment therapies. The area boasts early uptake of novel antiviral medications, including long-acting injectables for HIV, and oral therapies for COVID-19 and hepatitis. Market access is also facilitated by government programs, strong reimbursement systems, and a significant presence of large pharmaceutical companies, including Gilead Sciences, Merck, and AbbVie, which ensure trends in research, fast approvals, and penetration in the market. Moreover, public health programmes and insurance strongly increase patient access to avian antiviral drugs.
The Asia Pacific is a significant region in the antiviral drugs market over the forecast period on account of its vast population and its rapidly aging population, the increasing prevalence of viral infections such as hepatitis B and C, and increasing healthcare accessibility. Governments in countries such as China, India, and South Korea are ramping up vaccination programmes and adopting national plans to manage infectious diseases. (a) Rising awareness, economic growth, higher investment in local pharmaceutical production, and wider availability of generics at affordable costs are driving the market. Additionally, global health campaigns and public–private partnerships are enhancing drug availability to rural and underprivileged communities.
The antiviral drugs market in Europe is growing at a substantial rate compared to other regions due to the rise in demand for treatment with the need for chronic viral infections, which include HIV, hepatitis B and C, and seasonal influenza treatment in the region. As the country’s healthcare systems mature, and the active disease surveillance and early diagnosis programmes are in place and running, increasing the treatment rate and extending the patient coverage is made possible.
Furthermore, strong regulatory systems and public financing for infectious disease control resulted in rapid approval and uptake of novel antiviral treatments. These rates are being driven by countries such as Germany, the UK, and France, which have vigorous public health campaigns, a high level of vaccination coverage, and rapidly expanding clinical research collaborations within the region.
The antiviral drugs market trends in Latin America are rising at a moderate pace on account of improving healthcare infrastructure, rising disease awareness, and the government’s intervention in public health. Both countries, and others in Latin America, are broadening access to antiviral drugs through national health programs, especially for HIV and hepatitis.
The Middle East & Africa (MEA) expected the moderate growth in the antiviral drugs market analysis, notably propelled by government-backed plans on heavy disease burden ailments such as HIV, hepatitis B etc.; however, due to gaps in medicine penetration, achieving equity in coverage, challenges in affordability and utilization of imported drugs, the scope for further growth has proven restricted. Measures to bolster healthcare systems and local pharmaceutical production will ultimately underpin growth in the region going forward.
Key Players in the Antiviral Drugs Market:
The antiviral drugs market companies are Gilead Sciences, GlaxoSmithKline (GSK), Merck & Co., Bristol-Myers Squibb, AbbVie, Johnson & Johnson (Janssen Pharmaceuticals), Hoffmann-La Roche, Aurobindo Pharma, Cipla, Dr. Reddy’s Laboratories, ViiV Healthcare, Novartis, Mylan (Viatris), Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Abbott Laboratories, Sanofi, Pfizer, Shionogi, Apotex, and other players.
Recent Developments in the Antiviral Drugs Market:
-
June 2025 – Gilead Sciences, Inc. reported that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir), the company's twice-yearly injectable HIV-1 capsid inhibitor, for pre-exposure prophylaxis (PrEP). With this approval, Yeztugo becomes the first and sole twice-yearly PrEP choice to be marketed in the United States for adults and adolescents with a body weight of at least 35 kg who are at risk of acquiring HIV through sex.
- February 2024 – GSK plc announced that the U.S. Food and Drug Administration (FDA) has awarded Fast Track designation to bepirovirsen, an investigational antisense oligonucleotide (ASO) in development for the treatment of chronic hepatitis B (CHB). The designation is intended to expedite the development and review process for drugs treating serious diseases with unmet medical needs.
Antiviral Drugs Market Report Scope:
Report Attributes Details Market Size in 2024 USD 57.32 Billion Market Size by 2032 USD 86.59 Billion CAGR CAGR of 5.34% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Segments • By Type (Branded, Generics)
• By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others)
• By Application (HIV, Hepatitis, Herpes, Influenza, Coronavirus Infection)
• By Route of Administration (Oral, Parenteral, Topical, Other Routes of Administration)
• By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Company Profiles Gilead Sciences, GlaxoSmithKline (GSK), Merck & Co., Bristol-Myers Squibb, AbbVie, Johnson & Johnson (Janssen Pharmaceuticals), Hoffmann-La Roche, Aurobindo Pharma, Cipla, Dr. Reddy’s Laboratories, ViiV Healthcare, Novartis, Mylan (Viatris), Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Abbott Laboratories, Sanofii, Pfizer, Shionogi, Apotex, and other players.
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Type
2.3.2 Market Size By Drug Class
2.3.3 Market Size By Application
2.3.4Market Size By Route of Administration
2.3.5Market Size By Distribution Channel
2.4 Market Share & BPS Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Pricing Analysis & Forecast
4.1.1 Overview
4.1.2 Pricing Analysis & Forecast By Product, 2021–2032
4.1.3 Price Benchmarking by Key Players, 2024
4.2 Regulatory Landscape
4.2.1 Overview
4.2.2 Regulatory Trends By Key Countries
4.2.3 Regulatory Outlook By Product Type
4.3 Trade Analysis
4.3.1 Overview
4.3.2 Import Analysis (Value & Volume), By Country, 2021–2024
4.3.3 Export Analysis (Value & Volume), By Country, 2021–2024
4.3.4 Major Importing Countries
4.3.5 Major Exporting Countries
5. Antiviral Drugs Market Segmental Analysis & Forecast, By Type, 2021 – 2032, Value (USD Billion) & Volume (Litre)
5.1 Introduction
5.2 Branded
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Generics
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
6. Antiviral Drugs Market Segmental Analysis & Forecast, By Drug Class, 2021 – 2032, Value (USD Billion) & Volume (Litre)
6.1 Introduction
6.2 DNA Polymerase Inhibitors
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Reverse Transcriptase Inhibitors
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Protease Inhibitors
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
6.5 Neuraminidase Inhibitors
6.5.1 Key Trends
6.5.2 Market Size & Forecast, 2021 – 2032
7. Antiviral Drugs Market Segmental Analysis & Forecast, By Application, 2021 – 2032, Value (USD Billion) & Volume (Litre)
7.1 Introduction
7.2 HIV/AIDS
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Hepatitis
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
7.4 Herpes
7.4.1 Key Trends
7.4.2 Market Size & Forecast, 2021 – 2032
7.5 Influenza
7.5.1 Key Trends
7.5.2 Market Size & Forecast, 2021 – 2032
7.6 Coronavirus Infection
7.6.1 Key Trends
7.6.2 Market Size & Forecast, 2021 – 2032
8. Antiviral Drugs Market Segmental Analysis & Forecast, By Route of Administration, 2021 – 2032, Value (USD Billion) & Volume (Litre)
8.1 Introduction
8.2 Oral
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Parenteral
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Topical
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
9. Antiviral Drugs Market Segmental Analysis & Forecast, By Distribution Channel, 2021 – 2032, Value (USD Billion) & Volume (Litre)
9.1 Introduction
9.2 Hospital Pharmacy
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2021 – 2032
9.3 Retail Pharmacy
9.3.1 Key Trends
9.3.2 Market Size & Forecast, 2021 – 2032
9.4 Online Pharmacy
9.4.1 Key Trends
9.4.2 Market Size & Forecast, 2021 – 2032
10. Antiviral Drugs Market Segmental Analysis & Forecast By Region, 2021 – 2032, Value (USD Billion) & Volume (Litre)
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.2.3 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.2.4 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.2.5 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.2.6 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.2.7 Antiviral Drugs Market Size & Forecast, By Country, 2021 – 2032
10.2.7.1 USA
10.2.7.1.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.2.7.1.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.2.7.1.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.2.7.1.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.2.7.1.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.2.7.2 Canada
10.2.7.2.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.2.7.2.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.2.7.2.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.2.7.2.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.2.7.2.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3 Europe
10.3.1 Key Trends
10.3.2 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.3.3 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.4 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.3.5 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.6 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7 Antiviral Drugs Market Size & Forecast, By Country, 2021 – 2032
10.3.7.1 Germany
10.3.7.1.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.3.7.1.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.1.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.3.7.1.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.1.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.2 UK
10.3.7.2.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.3.7.2.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.2.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.3.7.2.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.2.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.3 France
10.3.7.3.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.3.7.3.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.3.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.3.7.3.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.3.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.4 Italy
10.3.7.4.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.3.7.4.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.4.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.3.7.4.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.4.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.5 Spain
10.3.7.5.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.3.7.5.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.5.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.3.7.5.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.5.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.6 Russia
10.3.7.6.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.3.7.6.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.6.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.3.7.6.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.6.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.7 Poland
10.3.7.7.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.3.7.7.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.7.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.3.7.7.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.7.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.8 Rest of Europe
10.3.7.8.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.3.7.8.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.3.7.8.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.3.7.8.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.8.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.4.3 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.4 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.4.5 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.6 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7 Antiviral Drugs Market Size & Forecast, By Country, 2021 – 2032
10.4.7.1 China
10.4.7.1.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.4.7.1.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.1.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.4.7.1.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.1.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.2 India
10.4.7.2.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.4.7.2.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.2.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.4.7.2.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.2.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.3 Japan
10.4.7.3.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.4.7.3.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.3.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.4.7.3.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.3.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.4 South Korea
10.4.7.4.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.4.7.4.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.4.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.4.7.4.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.4.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.5 Australia
10.4.7.5.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.4.7.5.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.5.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.4.7.5.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.5.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.6 ASEAN Countries
10.4.7.6.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.4.7.6.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.6.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.4.7.6.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.6.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.7 Rest of Asia-Pacific
10.4.7.7.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.4.7.7.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.4.7.7.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.4.7.7.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.7.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5 Latin America
10.5.1 Key Trends
10.5.2 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.5.3 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.4 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.5.5 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.6 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7 Antiviral Drugs Market Size & Forecast, By Country, 2021 – 2032
10.5.7.1 Brazil
10.5.7.1.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.5.7.1.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.1.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.5.7.1.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.1.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.2 Argentina
10.5.7.2.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.5.7.2.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.2.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.5.7.2.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.2.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.3 Mexico
10.5.7.3.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.5.7.3.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.3.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.5.7.3.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.3.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.4 Colombia
10.5.7.4.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.5.7.4.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.4.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.5.7.4.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.4.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.5 Rest of Latin America
10.5.7.5.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.5.7.5.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.5.7.5.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.5.7.5.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.5.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.6.3 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.4 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.6.5 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.6 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7 Antiviral Drugs Market Size & Forecast, By Country, 2021 – 2032
10.6.7.1 UAE
10.6.7.1.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.6.7.1.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.1.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.6.7.1.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.1.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.2 Saudi Arabia
10.6.7.2.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.6.7.2.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.2.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.6.7.2.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.2.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.3 Qatar
10.6.7.3.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.6.7.3.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.3.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.6.7.3.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.3.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.4 Egypt
10.6.7.4.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.6.7.4.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.4.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.6.7.4.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.4.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.5 South Africa
10.6.7.5.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.6.7.5.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.5.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.6.7.5.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.5.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.6 Rest of Middle East & Africa
10.6.7.6.1 Antiviral Drugs Market Size & Forecast, By Type, 2021 – 2032
10.6.7.6.2 Antiviral Drugs Market Size & Forecast, By Drug Class, 2021 – 2032
10.6.7.6.3 Antiviral Drugs Market Size & Forecast, By Application, 2021 – 2032
10.6.7.6.4 Antiviral Drugs Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.6.5 Antiviral Drugs Market Size & Forecast, By Distribution Channel, 2021 – 2032
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Key Strategies Adopted (%), By Key Players, 2024
11.2.2 Year-Wise Strategies & Development, 2021 – 2025
11.2.3 Number of Strategies Adopted by Key Players, 2024
11.3 Market Share Analysis, 2024
11.4 Product/Service & Application Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product/Service Heatmap By Key Players
11.4.3 Application Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6 Key Company Profiles
11.6.1 Gilead Sciences
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 SWOT Analysis
11.6.2 GlaxoSmithKline (GSK)
11.6.2.1 Company Overview & Snapshot
11.6.2.2 Product/Service Portfolio
11.6.2.3 Key Company Financials
11.6.2.4 SWOT Analysis
11.6.3 Merck & Co.
11.6.3.1 Company Overview & Snapshot
11.6.3.2 Product/Service Portfolio
11.6.3.3 Key Company Financials
11.6.3.4 SWOT Analysis
11.6.4 Bristol-Myers Squibb
11.6.4.1 Company Overview & Snapshot
11.6.4.2 Product/Service Portfolio
11.6.4.3 Key Company Financials
11.6.4.4 SWOT Analysis
11.6.5 AbbVie
11.6.5.1 Company Overview & Snapshot
11.6.5.2 Product/Service Portfolio
11.6.5.3 Key Company Financials
11.6.5.4 SWOT Analysis
11.6.6 Johnson & Johnson (Janssen Pharmaceuticals)
11.6.6.1 Company Overview & Snapshot
11.6.6.2 Product/Service Portfolio
11.6.6.3 Key Company Financials
11.6.6.4 SWOT Analysis
11.6.7 Hoffmann-La Roche
11.6.7.1 Company Overview & Snapshot
11.6.7.2 Product/Service Portfolio
11.6.7.3 Key Company Financials
11.6.7.4 SWOT Analysis
11.6.8 Aurobindo Pharma
11.6.8.1 Company Overview & Snapshot
11.6.8.2 Product/Service Portfolio
11.6.8.3 Key Company Financials
11.6.8.4 SWOT Analysis
11.6.9 Cipla
11.6.9.1 Company Overview & Snapshot
11.6.9.2 Product/Service Portfolio
11.6.9.3 Key Company Financials
11.6.9.4 SWOT Analysis
11.6.10 Dr. Reddy’s Laboratories
11.6.10.1 Company Overview & Snapshot
11.6.10.2 Product/Service Portfolio
11.6.10.3 Key Company Financials
11.6.10.4 SWOT Analysis
11.6.11 ViiV Healthcare
11.6.11.1 Company Overview & Snapshot
11.6.11.2 Product/Service Portfolio
11.6.11.3 Key Company Financials
11.6.11.4 SWOT Analysis
11.6.12 Novartis,
11.6.12.1 Company Overview & Snapshot
11.6.12.2 Product/Service Portfolio
11.6.12.3 Key Company Financials
11.6.12.4 SWOT Analysis
11.6.13 Mylan (Viatris)
11.6.13.1 Company Overview & Snapshot
11.6.13.2 Product/Service Portfolio
11.6.13.3 Key Company Financials
11.6.13.4 SWOT Analysis
11.6.14 Sun Pharmaceutical Industries
11.6.14.1 Company Overview & Snapshot
11.6.14.2 Product/Service Portfolio
11.6.14.3 Key Company Financials
11.6.14.4 SWOT Analysis
11.6.15 Teva Pharmaceutical Industries
11.6.15.1 Company Overview & Snapshot
11.6.15.2 Product/Service Portfolio
11.6.15.3 Key Company Financials
11.6.15.4 SWOT Analysis
11.6.16 Abbott Laboratories
11.6.16.1 Company Overview & Snapshot
11.6.16.2 Product/Service Portfolio
11.6.16.3 Key Company Financials
11.6.16.4 SWOT Analysis
11.6.17 Sanofi
11.6.17.1 Company Overview & Snapshot
11.6.17.2 Product/Service Portfolio
11.6.17.3 Key Company Financials
11.6.17.4 SWOT Analysis
11.6.18 Pfizer
11.6.18.1 Company Overview & Snapshot
11.6.18.2 Product/Service Portfolio
11.6.18.3 Key Company Financials
11.6.18.4 SWOT Analysis
11.6.19 Shionogi
11.6.19.1 Company Overview & Snapshot
11.6.19.2 Product/Service Portfolio
11.6.19.3 Key Company Financials
11.6.19.4 SWOT Analysis
11.6.20 Apotex
11.6.20.1 Company Overview & Snapshot
11.6.20.2 Product/Service Portfolio
11.6.20.3 Key Company Financials
11.6.20.4 SWOT Analysis
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions on Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List of Tables
15.2 List of Figures
Key Market Segments:
By Type
-
- Branded
- Generics
By Drug Class
-
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
By Application
-
- HIV/AIDS
- Hepatitis
- Herpes
- Influenza
- Coronavirus Infection
By Route of Administration
- Oral
- Parenteral
- Topical
By Distribution Channel
-
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Request for Segment Customization as per your Business Requirement: https://www.snsinsider.com/sample-request/3246
Regional Coverage:
North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Poland
- Turkey
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Australia
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Request for Country Level Research Report: https://www.snsinsider.com/sample-request/3246
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
